By LAURAN NEERGAARD and MIKE STOBBE
Associated Press
U.S. health officials have lifted an 11-day pause on Johnson & Johnson vaccinations following a recommendation by an expert panel. Advisers to the Centers for Disease Control and Prevention said Friday the benefits of the single-dose COVID-19 shot outweigh a rare risk of blood clots. Panel members said itâs critical that younger women be told about that risk so they can decide if theyâd rather choose another vaccine. The CDC and Food and Drug Administration agreed. European regulators earlier this week made a similar decision, deciding the clot risk was small enough to allow the rollout of J&Jâs shot.
US lifts pause, allowing J&J COVID-19 vaccinations to resume
Published
FOX 2 - U.S. health officials have lifted an 11-day pause on Johnson & Johnson vaccinations following a recommendation by an expert panel. Advisers to the Centers for Disease Control and Prevention said Friday the benefits of the single-dose COVID-19 shot outweigh a rare risk of blood clots.
Panel members said it s critical that younger women be told about that risk so they can decide if they d rather choose another vaccine. The CDC and Food and Drug Administration agreed. European regulators earlier this week made a similar decision, deciding the clot risk was small enough to allow the rollout of J&J s shot.
LAURAN NEERGAARD and MIKE STOBBE
Associated Press
U.S. health officials lifted an 11-day pause on COVID-19 vaccinations using Johnson & Johnson s single-dose shot on Friday, after scientific advisers decided its benefits outweigh a rare risk of blood clot.
The government uncovered 15 vaccine recipients who developed a highly unusual kind of blood clot, out of nearly 8 million people given the J&J shot. All were women, most under age 50. Three died, and seven remain hospitalized.
But ultimately Friday, the Food and Drug Administration and Centers for Disease Control and Prevention decided that J&J s one-and-done vaccine is critical to fight the pandemic â and that the small clot risk could be handled with warnings to help younger women decide if they should use that shot or an alternative.
pandemic, and now as
vaccines become more widely available, we are reporting on how our local schools, businesses and communities are returning to a more normal
future. There s never been more of a need for the kind of local, independent and unbiased journalism that The Day produces.
Please support our work by subscribing today.
U.S. to resume use of J&J vaccine after review of rare blood clot risk
In this March 3, 2021, file photo, U.S. Army medic Kristen Rogers, of Waxhaw, N.C., holds a vial of the Johnson & Johnson COVID-19 vaccine in North Miami, Fla. With the U.S. pause of the vaccine, authorities are weighing whether to resume the shots the way European regulators decided to with warnings of a “very rare” risk. New guidance is expected late Friday, April 23, after a government advisory panel deliberates a link between the shot and a handful of vaccine recipients who developed highly unusual blood clots. (AP Photo/Marta Lavandier, File)
editorial@post-journal.com
FILE - In this March 3, 2021, file photo, U.S. Army medic Kristen Rogers, of Waxhaw, N.C., holds a vial of the Johnson & Johnson COVID-19 vaccine in North Miami, Fla. With the U.S. pause of the vaccine, authorities are weighing whether to resume the shots the way European regulators decided to with warnings of a âvery rareâ risk. New guidance is expected late Friday, April 23, after a government advisory panel deliberates a link between the shot and a handful of vaccine recipients who developed highly unusual blood clots. (AP Photo/Marta Lavandier, File)
U.S. health officials lifted an 11-day pause on COVID-19 vaccinations using Johnson & Johnson’s single-dose shot on Friday, after scientific advisers decided its benefits outweigh a rare risk of blood clot.